Genetic Counselling — What It Is, When You Need It & What to Expect — Symptoms, Causes & Treatment | MyMedicPlus

Genetic counselling is a specialised healthcare service that provides individuals and families with information, education, and psychological support related to inherited genetic conditions and their implications for health and reproduction. It is delivered by trained clinical geneticists and genetic counsellors — healthcare professionals with specialist expertise in medical genetics, risk assessment, and counselling. Genetic counselling encompasses: interpreting and communicating the nature and implications of genetic conditions; calculating recurrence risks; discussing the options available for managing genetic risk (testing, surveillance, prophylactic intervention, reproductive choices); and providing non-directive, culturally sensitive support during the decision-making process. The field of genetic counselling has expanded significantly with advances in genomic medicine, including whole genome sequencing (WGS), polygenic risk scores, and targeted therapies for genetic conditions.

Genetic conditions arise from changes in DNA at the nucleotide level (mutations or variants), chromosomal level (deletions, duplications, translocations), or epigenetic level. Inheritance patterns: autosomal dominant (one mutant allele sufficient — e.g., Huntington's disease, BRCA1/2-related cancers, familial hypercholesterolaemia); autosomal recessive (two mutant alleles required — e.g., cystic fibrosis, sickle cell disease, thalassaemia, phenylketonuria — carrier frequency approximately 1 in 25 for each major condition); X-linked recessive (e.g., haemophilia A, Duchenne muscular dystrophy — predominantly affects males); X-linked dominant (e.g., Fragile X syndrome); mitochondrial (maternal transmission — e.g., Leber's hereditary optic neuropathy). Risk factors requiring genetic counselling referral: close consanguinity (increased risk of autosomal recessive conditions), multiple pregnancy losses, congenital malformations, intellectual disability, strong family cancer history (particularly early-onset), and ethnicity (certain conditions are more prevalent in specific populations — Tay-Sachs in Ashkenazi Jews, sickle cell in West Africans).

Genetic counselling itself is a service rather than a disease, but the conditions motivating referral present with diverse clinical features depending on the specific genetic disorder. Red flags for inherited cancer syndromes (BRCA1/2, Lynch syndrome, Li-Fraumeni): multiple first-degree relatives with the same cancer, early-onset cancer (breast before 40, colorectal before 50), bilateral cancer, rare cancer histology (medullary breast cancer, sebaceous adenoma), or multiple primary cancers. Hereditary metabolic disorders (PKU, MSUD, galactosaemia): neonatal encephalopathy, seizures, developmental delay, organomegaly, abnormal urine odour, and failure to thrive — detected by newborn screening. Chromosomal disorders (Down syndrome — trisomy 21, Turner syndrome — 45,X, Klinefelter — 47,XXY): characteristic dysmorphic features, intellectual disability, and associated organ malformations identified prenatally or in early childhood.

Genetic counselling begins with a comprehensive three-generation pedigree analysis (family history) to identify inheritance patterns and quantify recurrence risks. Diagnostic genetic testing modalities: chromosomal microarray — detects copy number variants (deletions, duplications) throughout the genome; gene panel testing — simultaneous sequencing of multiple disease-associated genes (e.g., inherited breast/ovarian cancer panel including BRCA1/2, PALB2, ATM, CHEK2); whole exome sequencing (WES) — sequences all protein-coding genes (~1% of genome); whole genome sequencing (WGS) — sequences the entire genome; including non-coding regions. Prenatal diagnosis: chorionic villus sampling (CVS — 10–12 weeks) or amniocentesis (15–18 weeks) for definitive fetal genetic testing; non-invasive prenatal testing (NIPT) — cell-free fetal DNA in maternal blood — screens for chromosomal aneuploidies (trisomy 21, 18, 13) and sex chromosome abnormalities with >99% sensitivity for trisomy 21. Biochemical testing (enzyme assays, metabolite levels) confirms specific metabolic disorders.

Genetic counselling itself is a consultative and educational service — management depends on the specific condition identified. For hereditary cancer syndromes: BRCA1/2 carriers — enhanced surveillance (annual breast MRI + mammogram from age 30; colonoscopy; CA125 + transvaginal ultrasound for ovarian cancer) or risk-reducing surgery (risk-reducing salpingo-oophorectomy reduces ovarian cancer risk by 80–96%; bilateral mastectomy reduces breast cancer risk by 90%); chemoprophylaxis (tamoxifen or raloxifene reduces breast cancer risk by 30–40%). For reproductive risk: preimplantation genetic testing (PGT-M) with IVF allows selection of unaffected embryos before implantation; prenatal diagnosis with the option of termination of an affected pregnancy; or natural conception with acceptance of a 25% or 50% risk for recessive or dominant conditions. For metabolic disorders: dietary restriction (PKU — phenylalanine restriction; galactosaemia — lactose-free diet); enzyme replacement therapy (Gaucher disease — imiglucerase); substrate reduction therapy; small molecule treatments (ivacaftor for CFTR-potentiator responsive mutations in cystic fibrosis).

Variants of uncertain significance (VUS) are identified in 20–40% of whole exome and genome sequencing results — VUS findings cause significant psychological distress and clinical uncertainty. Patients must be counselled that a VUS is neither confirmed pathogenic nor benign, and reclassification as evidence accumulates means results may change. Secondary (incidental) findings: the American College of Medical Genetics (ACMG) recommends reporting pathogenic variants in 73 specified genes unrelated to the primary indication ('ACMG 73 list') — patients must decide in advance whether to receive these unexpected results. Psychological impact of predictive testing: genetic testing for late-onset conditions (Huntington's disease, BRCA1/2) can cause severe anxiety, depression, and family relationship disruption regardless of result. Predictive testing for Huntington's disease (fully penetrant, autosomal dominant — 100% lifetime risk if mutation-positive) is particularly challenging; approximately 20% of at-risk individuals who begin the testing protocol choose not to proceed after pre-test counselling. Genetic discrimination in life insurance remains a real concern in many countries despite partial legislative protection (UK Code on Genetic Information; USA Genetic Information Nondiscrimination Act — GINA). Within families, disclosure of hereditary cancer or genetic results has complex implications — a positive result in one person informs relatives of their own risk, raising ethical questions about the duty to disclose versus the right not to know. False-positive results from inadequate direct-to-consumer (DTC) genetic testing can cause unnecessary prophylactic surgery (e.g., bilateral mastectomy for a false BRCA positive). Cascade testing, while beneficial, can reveal unexpected non-paternity and cause profound family disruption.

Carrier screening programmes identify individuals who carry one copy of an autosomal recessive gene variant — important for reproductive planning. Expanded carrier screening (ECS) panels now test for 200–300 conditions simultaneously and are increasingly offered to couples planning pregnancy. Newborn screening programmes (Guthrie test, tandem mass spectrometry) detect metabolic disorders (PKU, MCADD, sickle cell disease) at birth, enabling early treatment before irreversible harm occurs. Cascade testing — systematic testing of first-degree relatives of identified mutation carriers — maximises detection rates in families affected by hereditary cancers, FH, and other dominant conditions. Pre-test counselling ensures informed consent and prepares individuals for potential findings, including variants of uncertain significance (VUS), which are increasingly common with whole genome sequencing. Post-test counselling supports psychological adjustment and facilitates informed decision-making about management options.

Request a GP referral to clinical genetics or a genetic counsellor if: you have a first-degree relative diagnosed with a known hereditary cancer syndrome (BRCA1/2, Lynch syndrome, MUTYH, Li-Fraumeni); your family has a known hereditary condition (Huntington's disease, haemophilia, cystic fibrosis, muscular dystrophy, hereditary spastic paraplegia); two or more close relatives have the same cancer — especially at young ages; you are planning pregnancy and are in a consanguineous relationship, or your ethnic background confers higher risk for specific conditions (thalassaemia, sickle cell disease, Tay-Sachs); a newborn or child is diagnosed with dysmorphic features, intellectual disability, or a rare disorder of unknown cause; you or your partner has had two or more miscarriages; or a fetal anomaly is detected on prenatal ultrasound.